Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
36
NAUT Quote, Financials, Valuation and Earnings
Last price:
$2.03
Seasonality move
:
-17.65%
Day range:
$1.92 - $2.10
52-week range:
$0.62 - $2.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.52x
Volume:
254.9K
Avg. volume:
540.4K
1-year change:
5.73%
Market cap:
$256.4M
Revenue:
--
EPS (TTM):
-$0.50
Analysts' Opinion
-
Consensus RatingNautilus Biotechnology, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.50, Nautilus Biotechnology, Inc. has an estimated upside of 23.15% from its current price of $2.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.50 representing 100% downside risk from its current price of $2.03.
Fair Value
-
According to the consensus of 2 analysts, Nautilus Biotechnology, Inc. has 23.15% upside to fair value with a price target of $2.50 per share.
NAUT vs. S&P 500
-
Over the past 5 trading days, Nautilus Biotechnology, Inc. has underperformed the S&P 500 by -10.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nautilus Biotechnology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nautilus Biotechnology, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Nautilus Biotechnology, Inc. reported revenues of --.
Earnings Growth
-
Nautilus Biotechnology, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Nautilus Biotechnology, Inc. reported earnings per share of -$0.11.
Enterprise value:
152M
EV / Invested capital:
0.77x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.82x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$11.2M
Return On Assets:
-27.45%
Net Income Margin (TTM):
--
Return On Equity:
-32.15%
Return On Invested Capital:
-27.96%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$5M | -$6.4M | -$11.2M | -$1.6M | -$1.6M | |
| Operating Income | -$72.5M | -$81.5M | -$71.4M | -$19.1M | -$15.5M | |
| EBITDA | -$67.4M | -$75.1M | -$60.2M | -$17.5M | -$13.9M | |
| Diluted EPS | -$0.48 | -$0.56 | -$0.50 | -$0.13 | -$0.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $352.2M | $261.2M | $186.8M | $144.2M | $134.3M | |
| Total Assets | $385.3M | $359.3M | $318.3M | $259.7M | $200.9M | |
| Current Liabilities | $4.2M | $6.4M | $8.9M | $8.7M | $9M | |
| Total Liabilities | $7.5M | $34M | $41.1M | $36.3M | $31.8M | |
| Total Equity | $377.8M | $325.3M | $277.3M | $223.4M | $169.1M | |
| Total Debt | $3.6M | $27.5M | $32.2M | $27.6M | $22.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.2M | -$58.7M | -$52.6M | -$13.1M | -$11M | |
| Cash From Investing | -$66.7M | -$11.9M | $71.5M | -$7.5M | $452K | |
| Cash From Financing | $250K | $957K | $553K | $140K | -- | |
| Free Cash Flow | -$50.4M | -$61M | -$53.9M | -$13.8M | -$11.5M | |
NAUT
Sector
Market Cap
$256.4M
$28.5M
Price % of 52-Week High
79.92%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
0.53%
-1.33%
1-Year Price Total Return
5.73%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.11
200-day SMA
Buy
Level
$0.98
Bollinger Bands (100)
Buy
Level
0.58 - 1.62
Chaikin Money Flow
Buy
Level
3.7M
20-day SMA
Buy
Level
$2.00
Relative Strength Index (RSI14)
Buy
Level
55.76
ADX Line
Buy
Level
50.25
Williams %R
Neutral
Level
-68.9189
50-day SMA
Buy
Level
$1.49
MACD (12, 26)
Buy
Level
0.19
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
6.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6739)
Buy
CA Score
(Annual)
Level (-0.1316)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.3615)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal M. Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
Stock Forecast FAQ
In the current month, NAUT has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NAUT average analyst price target in the past 3 months is $2.50.
-
Where Will Nautilus Biotechnology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nautilus Biotechnology, Inc. share price will rise to $2.50 per share over the next 12 months.
-
What Do Analysts Say About Nautilus Biotechnology, Inc.?
Analysts are divided on their view about Nautilus Biotechnology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nautilus Biotechnology, Inc. is a Sell and believe this share price will drop from its current level to $2.50.
-
What Is Nautilus Biotechnology, Inc.'s Price Target?
The price target for Nautilus Biotechnology, Inc. over the next 1-year time period is forecast to be $2.50 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NAUT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nautilus Biotechnology, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NAUT?
You can purchase shares of Nautilus Biotechnology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nautilus Biotechnology, Inc. shares.
-
What Is The Nautilus Biotechnology, Inc. Share Price Today?
Nautilus Biotechnology, Inc. was last trading at $2.03 per share. This represents the most recent stock quote for Nautilus Biotechnology, Inc.. Yesterday, Nautilus Biotechnology, Inc. closed at $2.03 per share.
-
How To Buy Nautilus Biotechnology, Inc. Stock Online?
In order to purchase Nautilus Biotechnology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NAUT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NAUT
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
1.52x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
NAUT
Sector
Revenue growth
--
4.85%
Earnings growth
18%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.15
-$0.20
Profitability
NAUT
Sector
Profitability FY 2024
-$6.4M
$3.6M
Return on invested capital
-27.96%
-30.98%
Return on assets
-27.45%
-27.62%
Return on equity
-32.15%
-36.69%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Jan
27
Balance Sheet
NAUT
Sector
Total cash
$131.4M
$27.2M
Short term investments
$102.2M
$25.7M
Total assets
$242.7M
$79.7M
Long term debt
$22.8M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 29.72% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 46.38% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.68% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
